Q-omics provides the consensus-scored SNORA10B profile across patient tissues and cancer cell-line models. SNORA10B expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA10B is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, SNORA10B RNA expression shows 6,027 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUSC, and STAD as cancer lineages where SNORA10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA10B survival associations across molecular data types. SNORA10B RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA10B RNA expression–survival associations across cancer types. High SNORA10B expression shows unfavorable associations in KIRC, ACC, LUAD, THCA and LGG, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA10B RNA expression.
This table summarizes SNORA10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA10B shows lower tumor expression in LUSC and STAD. The LUSC box plot shows higher SNORA10B RNA expression in normal versus tumor tissue (log2 FC = −0.169, t-test p = .017).
This table shows molecular features associated with SNORA10B in patient tissues and cancer cell lines. In patient samples, SNORA10B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
